Vertex Pharmaceuticals Incorporated

179 articles about Vertex Pharmaceuticals Incorporated

• Vertex and Arbor Biotechnologies Establish Collaboration to Discover Novel Proteins to Advance Discovery of Gene-Editing Therapies

  1/3/2019

  Multi-year research collaboration funded by Vertex using Arbor’s proprietary research platform to enhance efforts in developing gene-editing therapies in five diseases

• Vertex Announces Positive Phase 2 Data in Third Proof-of-Concept Study with the NaV1.8 Inhibitor VX-150

  12/18/2018

  Treatment with the NaV1.8 inhibitor VX-150 showed significant relief of pain in patients with small fiber neuropathy and was generally well tolerated.

• Health Canada Grants Market Authorization for ORKAMBI® (lumacaftor/ivacaftor) for Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease

  12/13/2018

  ORKAMBI is the first medicine in Canada to treat the underlying cause of CF in young children with two copies of the F508del mutation

• Two Phase 3 Studies of the Triple Combination of VX-659, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis

  11/27/2018

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that treatment with the triple combination of the next-generation corrector VX-659, tezacaftor and ivacaftor resulted in statistically significant improvements in lung function (percent predicted forced expiratory volume in one second, or ppFEV1) in two Phase 3 studies in people with cystic fibrosis (CF).

• Vertex Reports Third-Quarter 2018 Financial Results

  10/24/2018

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2018 and reviewed recent progress with its approved and investigational medicines.

• Vertex Data Presented at North American Cystic Fibrosis Conference (NACFC) Demonstrate Rapid Progress Toward Expanding and Enhancing Options for Treating the Underlying Cause of Cystic Fibrosis

  10/18/2018

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that eight scientific abstracts from the company’s portfolio of cystic fibrosis (CF) medicines are being presented at the 32nd North American Cystic Fibrosis Conference taking place October 18-20, 2018 in Denver.

• Vertex to Announce Third Quarter 2018 Financial Results on October 24

  10/16/2018

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2018 financial results on Wednesday, October 24, 2018 after the financial markets close

• Vertex to Present at the Morgan Stanley Healthcare Conference on September 14

  9/11/2018

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Healthcare Conference on Friday, September 14, 2018 at 12:15 p.m. ET.

• Vertex and Genomics plc Establish Collaboration to Use Human Genetics and Data Science to Advance Discovery of Precision Medicines

  8/30/2018

  Multi-year collaboration combines expertise in genomics, machine learning and drug discovery to identify novel targets for innovative medicines

• Vertex Appoints Ludovic Fenaux as Senior Vice President, International Commercial Operations

  8/23/2018

  Ludovic Fenaux to lead Vertex’s expanding International organization

• Vertex Reports Second-Quarter 2018 Financial Results

  7/25/2018

  Second-quarter 2018 total CF product revenues of $750 million, a 46% increase compared to $514 million in the second quarter of 2017

• Vertex to Announce Second Quarter 2018 Financial Results on July 25

  7/12/2018

  Vertex Pharmaceuticals Incorporated will report its second quarter 2018 financial results on Wednesday, July 25, 2018 after the financial markets close.

• Vertex Opens Expanded Research Site in San Diego

  6/18/2018

  Vertex Pharmaceuticals Incorporated announced the opening of its new 170,000 square foot research facility in Torrey Pines, San Diego.

• Vertex Data Presented at European Cystic Fibrosis Society (ECFS) Conference Demonstrate Early and Long-Term Disease-Modifying Potential of Treating the Underlying Cause of CF

  6/7/2018

  Data from KALYDECO® (ivacaftor) studies show the potential to modify the long-term progression of the disease

• Vertex to Present at the Goldman Sachs Healthcare Conference on June 13

  6/6/2018

  Vertex Pharmaceuticals Incorporated announced that management will present at the Goldman Sachs Healthcare Conference

• Vertex Awards $400,000 in Scholarships to People Living with Cystic Fibrosis and Their Immediate Family Members

  5/1/2018

  Vertex Pharmaceuticals Incorporated announced the recipients of scholarships as part of its second All in for CF Scholarship program.

• Vertex Reports First-Quarter 2018 Financial Results

  4/26/2018

  Vertex Pharmaceuticals Incorporated reported consolidated financial results for the first quarter ended March 31, 2018.

• Vertex Initiates Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis

  4/26/2018

  Vertex Pharmaceuticals Incorporated announced that it is initiating two Phase 3 studies of VX-445.

• Q-State Biosciences and Vertex Pharmaceuticals Enter into Multi-Year Drug Discovery Collaboration

  4/4/2018

  Q-State Biosciences, Inc. today announced that the company has entered into a strategic collaboration with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) to discover drugs using Q-State’s novel Optopatch™ platform.

• Fading Vertex Pharmaceuticals (CA) Drug Incivek was Also Fastest to Become a Blockbuster

  11/1/2013